- Home
- GWRE vs BMRN Comparison
GWRE vs BMRN Comparison
Compare GWRE & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GWRE | BMRN |
|---|---|---|
| Founded | 2001 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 11.4B |
| IPO Year | 2011 | 1999 |
Fundamental Metrics
Financial Performance| Metric | GWRE | BMRN |
|---|---|---|
| Price | $175.59 | $67.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 18 |
| Target Price | ★ $251.31 | $88.22 |
| AVG Volume (30 Days) | 1.2M | ★ 2.1M |
| Earning Date | 06-02-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1257.14 | N/A |
| EPS | ★ 1.26 | 0.77 |
| Revenue | $719,514,000.00 | ★ $1,313,646,000.00 |
| Revenue This Year | $22.67 | $15.02 |
| Revenue Next Year | $15.73 | $12.23 |
| P/E Ratio | $144.94 | ★ $88.99 |
| Revenue Growth | 8.84 | ★ 17.62 |
| 52 Week Low | $102.30 | $49.26 |
| 52 Week High | $272.60 | $70.98 |
Technical Indicators
Market Signals| Indicator | GWRE | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 63.96 | 66.40 |
| Support Level | $121.28 | $58.03 |
| Resistance Level | $226.57 | N/A |
| Average True Range (ATR) | 8.15 | 2.13 |
| MACD | 1.63 | 0.74 |
| Stochastic Oscillator | 75.50 | 70.72 |
Price Performance
Historical ComparisonAbout GWRE Guidewire Software Inc.
Guidewire Software provides cloud-based software solutions for property and casualty insurers. The flagship product, InsuranceSuite is a system of record and comprises ClaimCenter, a claims management system; PolicyCenter, a policy management system including policy definitions, quotas, issuance, maintenance, and renewal; and BillingCenter, for billing management, payment plans, and agent commissions. The company also offers InsuranceNow, a midmarket offering, as well as a variety of other add-on applications and services.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.